CompletedNCT05473741
Breakthrough symptoms during long-acting schizophrenia treatment
About this title
Read the official source — NCT05473741Observational studyAges 18–65Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
Study information
Study start dateStarted: January 11, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 51
- Sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- Hospital / academic medical center
- Study type
- Observational
- Intervention type
- Drug
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05473741
- Official title
Show the full official title
Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Second Generation Long-Acting Injectable Antipsychotic Medications.
Who was this study for?
Listed age limits: 18 years to 65 years.
